Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for Protalix BioTherapeutics in a research report issued to clients and investors on Monday, February 3rd. HC Wainwright analyst R. Selvaraju expects that the company will earn $0.03 per share for the quarter. HC Wainwright currently has a "Buy" rating and a $15.00 target price on the stock. The consensus estimate for Protalix BioTherapeutics' current full-year earnings is $0.02 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics' Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.05 EPS and Q4 2025 earnings at $0.06 EPS.
Separately, StockNews.com downgraded shares of Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a research report on Tuesday.
Get Our Latest Analysis on Protalix BioTherapeutics
Protalix BioTherapeutics Price Performance
Shares of PLX stock traded up $0.02 during mid-day trading on Tuesday, hitting $2.69. The stock had a trading volume of 914,329 shares, compared to its average volume of 727,310. The firm has a market cap of $198.06 million, a PE ratio of -20.69 and a beta of 0.75. The company's 50-day simple moving average is $2.03 and its 200-day simple moving average is $1.44. Protalix BioTherapeutics has a fifty-two week low of $0.82 and a fifty-two week high of $2.76.
Institutional Trading of Protalix BioTherapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Squarepoint Ops LLC boosted its stake in shares of Protalix BioTherapeutics by 673.3% during the 2nd quarter. Squarepoint Ops LLC now owns 137,764 shares of the company's stock worth $161,000 after acquiring an additional 119,949 shares in the last quarter. AQR Capital Management LLC acquired a new position in Protalix BioTherapeutics during the second quarter worth $67,000. Virtu Financial LLC purchased a new stake in Protalix BioTherapeutics during the third quarter worth $44,000. Sanctuary Advisors LLC acquired a new stake in Protalix BioTherapeutics in the third quarter valued at $38,000. Finally, XTX Topco Ltd purchased a new position in shares of Protalix BioTherapeutics in the third quarter valued at $36,000. Institutional investors and hedge funds own 16.53% of the company's stock.
About Protalix BioTherapeutics
(
Get Free Report)
Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
Featured Articles
Before you consider Protalix BioTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protalix BioTherapeutics wasn't on the list.
While Protalix BioTherapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for February 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
